buprenorphine hydrochloride

USDailyMed:Buprenorphine AU:C N02AE01(WHO)N07BC01(WHO) AU:S8(Controlled drug)BR:Class A1(Narcotic drugs)CA:Schedule IDE:Anlage III(Special prescription form required)UK:Class CUS:Schedule IIIUN:Psychotropic Schedule IIIEU:Rx-onlySE: Förteckning IV (2S)-2-[(5R,6R,7R,14S)-17-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol 52485-79-7Y 644073 1670 DB00921Y 559124Y 40D3SCR4GZ D07132Y CHEBI:3216Y ChEMBL511142N DTXSID2022705 Interactive image Oc7ccc5c1c7O[C@H]3[C@]6(OC)[C@H](C[C@@]2([C@H](N(CC[C@@]123)CC4CC4)C5)CC6)[C@@](O)(C)C(C)(C)C InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1YKey:RMRJXGBAOAMLHD-IHFGGWKQSA-NY Buprenorphineis anopioidused to treatopioid use disorder, acutepain, andchronic pain.It can be usedunder the tongue (sublingual),in the cheek (buccal), byinjection(intravenousandsubcutaneous), as askin patch (transdermal), or as animplant. In the United States, the combination formulation ofbuprenorphine/naloxone(Suboxone) is usually prescribed to discourage misuse by injection.Maximum pain relief is generally within an hour with effects up to 24 hours.Buprenorphine affects different types ofopioid receptorsin different ways.Depending on the type ofopioid receptor, it may be anagonist,partial agonist, orantagonist.Buprenorphine's activity as an agonist/antagonist is important in the treatment of opioid use disorder: it relieves withdrawal symptoms from other opioids and induces some euphoria (primarily when first starting treatment if one is not already opioid tolerant/dependent), but also blocks the ability for many other opioids, including heroin, to cause an effect.‍‍‍‍‍‍​​​‍​​​​​​ Unlike full agonists like heroin ormethadone, buprenorphine has a ceiling effect, such that taking more medicine past a certain point will not increase the effects of the drug. Being a partial MOR agonist, buprenorphine offers flexibility to prescribers treating opioid use disorder as the dosage can be easily adjusted. Side effects may includerespiratory depression(decreased breathing), sleepiness,adrenal insufficiency, changes in heart electrophysiology (QT prolongation),low blood pressure,allergic reactions,constipation, and opioid addiction.Among those with a history ofseizures, a risk exists of further seizures.Opioid withdrawalfollowing stopping buprenorphine is generally less severe than with other opioids.Whether use duringpregnancyis safe is unclear, but use whilebreastfeedingis probably safe, since the dose the infant receives is 1–2% that of the maternal dose, on a weight basis. Buprenorphine was patented in 1965, FDA approved for medical use as an analgesic in 1981, and FDA approved for treating opioid use disorder in 2002.It is on theWorld Health Organization's List of Essential Medicines.Despite originally being marketed as an analgesic it is far more commonly prescribed and used to treat opioid use disorders, such as addiction toheroin.In 2020, it was the 186th most commonly prescribed medication in the United States, with more than 2.8million prescriptions. Buprenorphine is generally used as a medication for treating opioid use disorder. In the United States, buprenorphine hydrochloride (and a combination formula, buprenorphine hydrochloride/naloxone,) areschedule IIIcontrolled substances. Buprenorphine does not produce the same sense of euphoria and/or "sense of well-being" as reported in use of full-agonist opioids. A "ceiling effect"is observed in regards to the potentially fatal side effects of other opioids, such as respiratory depression. While the medication may produce comparably mild side effects to that of other drugs in its classification, it still carries some abuse potential.